Evidence map›Paper›PMID 25403776›Full record

ArticleObesity surgery2015

Roux-en-Y gastric bypass decreases pro-inflammatory and thrombotic biomarkers in individuals with extreme obesity.

Bárbara Dal Molin Netto, Solange Cravo Bettini, Ana Paula Grotti Clemente, Joana Pereira de Carvalho Ferreira, Katia Boritza, Sandy de Fátima Souza, Maria Emilia Von der Heyde, Carrie P Earthman, Ana R Dâmaso

Abstract read
PubMed Publisher
In one paragraph

Article in Obesity surgery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 5 pooled it
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 5 syntheses or guidelines pooled it, 73 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Multidisciplinary Therapy to Target Obesity and Its Complications in Adult Population: A Narrative Review.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Microbiome Medicine: Microbiota in Development and Management of Cardiovascular Diseases.Endocrine, metabolic & immune disorders drug targets · 2022
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Bárbara Dal Molin NettoPost-Graduate Program of Nutrition, Universidade Federal de São Paulo - UNIFESP, Rua Marselhesa, 630 - Vila Clementino, São Paulo, SP, 04020-060, Brazil, barbaradmnetto@gmail.com.
Solange Cravo Bettini
Ana Paula Grotti Clemente
Joana Pereira de Carvalho Ferreira
Katia Boritza
Sandy de Fátima Souza
Maria Emilia Von der Heyde
Carrie P Earthman
Ana R Dâmaso
Universidade Federal de São Paulo · BRHospital de Clínicas Universidade Federal do Paraná · BRUniversidade Federal do Paraná · BRUniversity of Minnesota · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe low-grade inflammatory state in obesity leads to insulin resistance and endothelial dysfunction, which promote cardiovascular diseases in individuals with obesity. The purpose of this study was to evaluate the early effects of weight loss achieved through bariatric surgery on the inflammatory and prothrombotic states. This study also aimed to identify the role of hyperleptinemia on the prothrombotic state.

methodsThe sample was composed of 41 extremely obese who underwent Roux-en-Y gastric bypass (RYGB). Anthropometric and clinical data, and biochemical markers of inflammation were collected prior to surgery and 6 months post-RYGB.

resultsIt was found that plasminogen activator inhibitor-1 (PAI-1) concentrations were higher among extremely obese individuals with hyperleptinemia than in those without hyperleptinemia (p < 0.01).In relation to the baseline, post-surgery body mass index (BMI) was reduced by 12.9 kg/m(2), corresponding to 63.50 % of excess weight loss. Additionally, waist circumference was found to decrease significantly from 126.2 to 101.4 cm. Plasma total cholesterol (p < 0.01), LDL cholesterol (p = 0.02), triglycerides (p < 0.01), and glucose (p = 0.01) were also found to decrease. Pro-inflammatory biomarkers were observed to decrease: PAI-1 by 55.9 ± 6.0 % (p < 0.01), C-reactive protein (CRP) by 18.8 ± 3.4 % (p < 0.01), intercellular adhesion molecule-1 (ICAM-1) by 89.9 ± 5.7 % (p < 0.01), leptin by 27.9 ± 3.2 % (p < 0.01), and resistin by 69.3 ± 5.8 % (p < 0.01). Additionally, significant decreases of tumor necrosis factor alpha (TNF-α) and leptin/adiponectin ratio were observed. Anti-inflammatory cytokines adiponectin and interleukin-10 (IL-10) were significantly increased (170.7 ± 82.5 %, p < 0.01; 122.7 ± 55.1 %, p = 0.02). CRP levels were predictive of ICAM-1 (p = 0.04), and changes in leptin concentrations were associated with decreased PAI-1 levels (p = 0.03).

conclusionsWe observed that individuals with obesity that have hyperleptinemia have higher circulating PAI-1 levels, which could indicate increased risk for cardiovascular disease. The biomarkers of inflammation and thrombosis measured in this study decreased after RYGB, suggesting that the surgery may be effective in reducing pro-inflammatory and thrombotic risk in individuals with extreme obesity.

Indexed as

Gastric BypassAdiponectinAdultBiomarkersBody Mass IndexC-Reactive ProteinFemaleHumansInflammationInsulin ResistanceIntercellular Adhesion Molecule-1Interleukin-10LeptinMaleMiddle AgedObesityAdiponectinADIPOQ protein, humanBiomarkersC-Reactive ProteinIL10 protein, humanIntercellular Adhesion Molecule-1Interleukin-10LeptinPlasminogen Activator Inhibitor 1SERPINE1 protein, humanTriglycerides

Identifiers

PMID25403776
OpenAlexW1986056701

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.